Last reviewed · How we verify
Group L
At a glance
| Generic name | Group L |
|---|---|
| Also known as | lidotopcaplasma |
| Sponsor | BON WOOK KOO |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Millet Seed Extract in Telogen Effluvium Treatment (NA)
- The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics (NA)
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
- Spot Analysis of Natriuresis to Guide up- or Down-titration of Diuretic Therapy in Ambulatory Patients With Chronic Heart Failure (NA)
- Asymmetric High-Flow Nasal Cannula During Pulmonary Rehabilitation in COPD (NA)
- Canadian Critical Care Comparative Effectiveness Platform (PHASE3)
- Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma (PHASE1)
- Diagnosis of Pheochromocytoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Group L CI brief — competitive landscape report
- Group L updates RSS · CI watch RSS
- BON WOOK KOO portfolio CI